BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karpf DM, Sørensen BB, Hermit MB, Holmberg HL, Tranholm M, Bysted BV, Groth AV, Bjørn SE, Stennicke HR. Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa. Thromb Res 2011;128:191-5. [PMID: 21429564 DOI: 10.1016/j.thromres.2011.02.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Larsen MS, Juul RV, Groth AV, Simonsson US, Kristensen AT, Knudsen T, Agersø H, Kreilgaard M. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia. European Journal of Pharmaceutical Sciences 2018;115:196-203. [DOI: 10.1016/j.ejps.2018.01.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Farys M, Ginn CL, Badescu GO, Peciak K, Pawlisz EM, Khalili H, Brocchini SJ. Chemical and Genetic Modification. In: Gad SC, editor. Pharmaceutical Sciences Encyclopedia. Hoboken: John Wiley & Sons, Inc.; 2010. pp. 1-52. [DOI: 10.1002/9780470571224.pse508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Behrens C, Buchardt J. Sialyltransferase-mediated glycoPEGylation. Polymer-Protein Conjugates. Elsevier; 2020. pp. 251-69. [DOI: 10.1016/b978-0-444-64081-9.00012-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Zollner S, Schuermann D, Raquet E, Mueller-Cohrs J, Weimer T, Pragst I, Dickneite G, Schulte S. Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). J Thromb Haemost 2014;12:220-8. [PMID: 24641308 DOI: 10.1111/jth.12477] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
5 Clark CA, Vatsyayan R, Hedner U, Esmon CT, Pendurthi UR, Rao LV. Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa. J Thromb Haemost 2012;10:2383-91. [PMID: 22950420 DOI: 10.1111/j.1538-7836.2012.04917.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
6 Mahmood I. Allometric scaling and prediction of concentration-time profiles of coagulation factors in humans from animals. Xenobiotica 2013;43:774-9. [DOI: 10.3109/00498254.2013.766778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Johansen PB, Tranholm M, Haaning J, Knudsen T. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules. Haemophilia 2016;22:625-31. [DOI: 10.1111/hae.12907] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
8 Gomez K, Klamroth R, Mahlangu J, Mancuso ME, Mingot ME, Ozelo MC. Key issues in inhibitor management in patients with haemophilia. Blood Transfus 2014;12 Suppl 1:s319-29. [PMID: 24333092 DOI: 10.2450/2013.0246-12] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
9 Mannucci PM. Half-life extension technologies for haemostatic agents. Thromb Haemost 2015;113:165-76. [PMID: 25274414 DOI: 10.1160/TH14-04-0332] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
10 Mohammed BM, Monroe DM, Gailani D. Mouse models of hemostasis. Platelets 2020;31:417-22. [PMID: 31992118 DOI: 10.1080/09537104.2020.1719056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Mahmood I. Designing first-in-human dose of coagulation factors: application of pharmacokinetic allometric scaling. Haemophilia 2014;20:32-8. [PMID: 23855969 DOI: 10.1111/hae.12231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
12 Duan X, Tang M, Zhang J, Yu H, Xu R. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A. Blood Coagulation & Fibrinolysis 2014;25:539-52. [DOI: 10.1097/mbc.0000000000000098] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013;11:84-98. [DOI: 10.1111/jth.12270] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
14 Horava SD, Peppas NA. Recent advances in hemophilia B therapy. Drug Deliv Transl Res 2017;7:359-71. [PMID: 28243977 DOI: 10.1007/s13346-017-0365-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Shibeko AM, Woodle SA, Lee TK, Ovanesov MV. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 2012;120:891-9. [PMID: 22563088 DOI: 10.1182/blood-2011-11-393371] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
16 Metzner HJ, Pipe SW, Weimer T, Schulte S. Extending the pharmacokinetic half-life of coagulation factors by fusion to recombinant albumin. Thromb Haemost 2013;110:931-9. [PMID: 24178510 DOI: 10.1160/TH13-03-0213] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
17 Ferrarese M, Pignani S, Lombardi S, Balestra D, Bernardi F, Pinotti M, Branchini A. The carboxyl-terminal region of human coagulation factor X as a natural linker for fusion strategies. Thromb Res 2019;173:4-11. [PMID: 30453126 DOI: 10.1016/j.thromres.2018.11.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]